Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service
Amaro-Hosey, Kristopher (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Danés Carreras, Immaculada (Vall d'Hebron Institut de Recerca (VHIR))
Vendrell Bosch, Lourdes (Vall d'Hebron Institut de Recerca (VHIR))
Alonso, Laura (Vall d'Hebron Institut d'Oncologia)
Renedo-Miró, Berta (Hospital Universitari Vall d'Hebron)
Gros, Luis (Vall d'Hebron Institut d'Oncologia)
Vidal Guitart, Xavier (Hospital Universitari Vall d'Hebron)
Cereza García, Gloria (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Agustí Escasany, M. Antònia (Vall d'Hebron Institut de Recerca (VHIR))

Data:	2021
Resum:	Introduction: Drugs used in oncological diseases are frequently related to adverse drug reactions (ADR). Few studies have analyzed the toxicity of cancer treatments in children in real practice. Methods: An observational, longitudinal and prospective study has been carried out in an Oncohematology Service of a tertiary hospital. During 2017, patients exposed to one or more drugs of a previously agreed list were identified and followed-up for at least 6 months each. Characteristics of ADR, incidence, causality and possible preventability, have been evaluated. Results: 72 patients have been treated with at least one study drug, and 159 ADR episodes involving at least one of these drugs have been identified, with a total of 293 ADR. Most episodes required hospital admission (35. 2%) or happened during the hospital stay (33%), and 91. 2% were severe. Blood disorders were the most frequent ADR (96; 32. 8%), related to thioguanine (42) and pegaspargase (39) mainly, followed by infections (86; 29. 4%) related to thioguanine (32), pegaspargase (27), Erwinia asparaginase (14) and rituximab (13). Two ADR were unknown. Most ADR were dose-dependent or expectable (.
Ajuts:	Ministerio de Economía y Competitividad PI16/02018
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Pharmacovigilance ; Adverse drug reactions ; Pediatrics ; Hematology ; Neoplasms ; Pegaspargase ; Thioguanine ; Incidence
Publicat a:	Frontiers in Pharmacology, Vol. 12 (may 2021) , ISSN 1663-9812

DOI: 10.3389/fphar.2021.670945
PMID: 34025429

9 p, 611.2 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats